// App-Quantinova.ai

: Sustained and durable response up to 24 weeks after last dose observed in a Phase 2a study (NCT03754309) of Amlitelimab (KY1005, SAR445229) a novel non-depleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe Atopic Dermatitis (AD)

Researchers

Presenter

  • Stephan Weidinger

Principal Investigators

  • Thomas Bieber

  • Michael Cork

  • Adam Reich

  • Sally Gilbert

  • Nuala Brennan

  • Sonia Quaratino

  • Rosamund Wilson

  • Ben Porter-Brown

Medical Centers

  • Department of Dermatology and Allergy, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany

  • Sheffield Dermatology Research, University of Sheffield, Sheffield, UK

  • Department of Dermatology, University of Rzeszow, Rzeszow, POLAND

  • Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, GERMANY

  • Spica Consultants Ltd, Marlborough, UNITED KINGDOM

  • Clinical Development, Kymab Ltd (A Sanofi Company), Cambridge, UNITED KINGDOM

Locations

  • United Kingdom

  • United States

  • Poland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • KY1005

  • OX40L

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • NCT03754309

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved